Mumbai: Sun Pharma Advanced Research Company Ltd. has announced submission of an Investigational New Drug (IND) application ...

UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell ...

Indian pharma stocks fell for the third consecutive session amid concerns of potential US tariffs on pharmaceutical imports.

Sun Pharma shares dipped in the intraday trading session on Friday, March 28. The Indian equity markets are in a tight spot, ...

From cars to generics, the impact is expected to be sweeping. A 25% levy on imported autos and parts is the showpiece of ...

Vadodara: Sun Pharmaceutical Industries Limited's investee company, Lyndra Therapeutics Inc., has ceased operations due to ...

Stay up-to-date with the Sun Pharma Stock Liveblog, your trusted source for real-time updates and thorough analysis of a ...

In New Jersey, new initiatives support investment and job growth in the artificial intelligence and film and digital media ...

Sun Pharmaceutical Industries Ltd. closed 9.91% short of its 52-week high of 1,960.20 rupees, which the company reached on ...

Sun Pharmaceutical Industries Ltd. closed 10.33% short of its 52-week high of 1,960.20 rupees, which the company reached on ...

Stock market today: Indian markets continued their stellar run for the sixth consecutive trading session on Monday, March 24, with Nifty 50 and Sensex surging another 1% each at the day's highs ...

SBO-154, our first ADC is ready to advance in phase 1 with this IND submission, and this is an important milestone for SPARC as we hope to improve lives of cancer patients globally. said Anil Raghavan ...